相似文献
1
A little light on the Mayo: justifying reversal of the Federal Circuit's Association for Molecular Pathology decision.
Seton Hall Law Rev. 2014;44(1):171-206.
2
DNA patent decision leaves questions for diagnostics.
Nat Rev Drug Discov. 2011 Aug 31;10(9):650-1. doi: 10.1038/nrd3548.
3
The Federal Circuit's decision in Myriad: isolated DNA molecules are patentable subject matter.
Am Univ Law Rev. 2011;61(2):443-56.
4
5
Patently unpatentable: implications of the Myriad court decision on genetic diagnostics.
Trends Biotechnol. 2010 Nov;28(11):548-51. doi: 10.1016/j.tibtech.2010.08.005.
6
Diagnostic method patents and harms to follow-on innovation.
Harv Law Rev. 2013 Mar;126(5):1370-91.
7
Gene patents and personalized cancer care: impact of the Myriad case on clinical oncology.
J Clin Oncol. 2013 Jul 20;31(21):2743-8. doi: 10.1200/JCO.2013.49.7388. Epub 2013 Jun 13.
8
Intellectual property and regulation of molecular pathology tests.
Cancer J. 2014 Jan-Feb;20(1):85-90. doi: 10.1097/PPO.0000000000000012.
9
Emerging patent issues in genomic diagnostics.
Nat Biotechnol. 2006 Aug;24(8):939-41. doi: 10.1038/nbt0806-939.
10
The future of gene patents and the implications for medicine.
JAMA Intern Med. 2013 Sep 23;173(17):1569-70. doi: 10.1001/jamainternmed.2013.10153.
Zotero 插件